Human papillomavirus vaccine disease impact beyond expectations.


Journal

Current opinion in virology
ISSN: 1879-6265
Titre abrégé: Curr Opin Virol
Pays: Netherlands
ID NLM: 101560941

Informations de publication

Date de publication:
12 2019
Historique:
received: 25 05 2019
revised: 11 06 2019
accepted: 12 06 2019
pubmed: 6 8 2019
medline: 5 8 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

Since 2006, 115 countries and territories have introduced human papillomavirus (HPV) vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV vaccines. Many countries, mainly high-income and with high screening coverage, are already reporting a visible impact of the HPV vaccine on HPV-related diseases. Others, largely low-income and middle-income countries, are introducing HPV vaccine to control HPV diseases that will undoubtedly generate a similar impact. In this review, we will summarize the compelling evidence of the impact of vaccines in reducing the burden of HPV-related disease. The data support additional efforts to make HPV vaccines widely available to adolescent girls in the countries that bear the vast majority of cervical cancer-related morbidity and mortality.

Identifiants

pubmed: 31382121
pii: S1879-6257(19)30043-4
doi: 10.1016/j.coviro.2019.06.006
pii:
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-22

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Silvia de Sanjose (S)

PATH, Sexual and Reproductive Health, Seattle, WA, USA; CIBER Epidemiologia y Salud Publica, Madrid, Spain. Electronic address: sdesanjose@path.org.

Maria Brotons (M)

Unit of Infections and Cancer-Information and Interventions, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

D Scott LaMontagne (DS)

PATH, Center for Vaccine Innovation & Access, Seattle, WA, USA.

Laia Bruni (L)

Unit of Infections and Cancer-Information and Interventions, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Barcelona, Spain; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH